ADRO Aduro Biotech Inc.

1.18
-0.01  -1%
Previous Close 1.19
Open 1.19
Price To Book 1.16
Market Cap 95,007,062
Shares 80,514,459
Volume 763,775
Short Ratio
Av. Daily Volume 804,168
Stock charts supplied by TradingView

NewsSee all news

  1. Aduro Biotech Provides Business Update and Reports Third Quarter 2019 Financial Results

    BERKELEY, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and

  2. Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

    BERKELEY, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and

  3. Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference

    BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Andrea van Elsas, chief scientific officer of Aduro, is scheduled to present at the 2019 Cantor Global

  4. Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

    BERKELEY, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING)

  5. Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    BERKELEY, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Initial data at SITC November 2018 noted 2/40 PRs and 11 with SD.
ADU-S100
Solid tumors or lymphomas
Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas - ECLIPSE trial
Pancreatic cancer
Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial
Pancreatic cancer
Noted December 12, 2017 that development to be discontinued.
CRS-207 with pembrolizumab
Mesothelioma - cancer
Phase 1 ongoing.
pLADD
Colorectal Cancer
Phase 1 ongoing.
pLADD
Colorectal Cancer
Phase 1b initiation announced June 7, 2018.
ADU-214 with Nivolumab
Non-Small Cell Lung Cancer
Phase 1 final data due 2020.
ADU-S100 and Spartalizumab
Solid tumors or lymphomas
Phase 1 commencement of dosing announced February 11, 2019.
ADU-S100 and ipilimumab
Melanoma
Phase 1 data due 2020.
BION-1301
IgA Nephropathy
Phase 1b/2 initiation of dosing announced September 4, 2019 with initial data due 2020.
ADU-S100 and pembrolizumab
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase 1 data presented at SITC November 2019 noted one patient in each of the monotherapy and combo arms showed a partial response.
MK-5890 and pembrolizumab
Solid tumors

Latest News

  1. Aduro Biotech Provides Business Update and Reports Third Quarter 2019 Financial Results

    BERKELEY, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and

  2. Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

    BERKELEY, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and

  3. Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference

    BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Andrea van Elsas, chief scientific officer of Aduro, is scheduled to present at the 2019 Cantor Global

  4. Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

    BERKELEY, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING)

  5. Aduro Biotech to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    BERKELEY, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the